Lyra Therapeutics Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Lyra Therapeutics hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

-226.8%

Rückkaufsrendite

Gesamte Aktionärsrendite	-226.8%
Zukünftige Dividendenrendite	0%
Wachstum der Dividende	n/a
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Ausschüttungsquote	n/a

Jüngste Updates zu Dividenden und Rückkäufen

Keine Aktualisierungen

Recent updates

Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?

Jan 25

We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully

Sep 10

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Mar 12

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Mar 30

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?

Dec 14

We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth

Aug 28

We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate

May 04

How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?

Mar 05

Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth

Jan 11

Lyra Therapeutics down 19% underwhelming data from lead program

Dec 07

Lyra Therapeutics: An Intriguing Risk/Reward Proposition Tackling Chronic Rhinosinusitis

Nov 24

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von LYRA in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von LYRA gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Lyra Therapeutics Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von LYRA im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (LYRA)	n/a
Untere 25 % des Marktes (US)	1.3%
Markt Top 25 % (US)	4.2%
Branchendurchschnitt (Pharmaceuticals)	2.4%
Analystenprognose (LYRA) (bis zu 3 Jahre)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von LYRA im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von LYRA im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von LYRA, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da LYRA keine Ausschüttungen gemeldet hat.

Lyra Therapeutics Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Updates zu Dividenden und Rückkäufen

Recent updates

Lyra Therapeutics, Inc. Fully Enrolls Pivotal Phase 3 Enlighten 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

Lyra Therapeutics, Inc. Announces Impairment of Property and Equipment for the Quarter Ended June 30, 2024

Lyra Therapeutics, Inc. Announces Impairment of Property and Equipment for the Quarter Ended June 30, 2024

Lyra Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Lyra Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Price target decreased by 8.3% to US$11.00

Lyra Therapeutics, Inc. Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis

Price target decreased by 8.3% to US$11.00

Consensus revenue estimates increase by 14%, EPS downgraded

New major risk - Financial position

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Lyra Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?

Executive Chairman recently bought US$74k worth of stock

Consensus revenue estimates increase by 17%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Lyra Therapeutics, Inc Announces Appointment of Ronan O’Brien as Chief Legal Officer

Price target increased by 15% to US$12.20

Lyra Therapeutics Announces Positive Topline Results from Beacon Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis in Patients with Prior Ethmoid Sinus Surgery

We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 24%

Consensus EPS estimates upgraded to US$1.66 loss

Lyra Therapeutics, Inc. announced that it expects to receive $44.11725 million in funding

Consensus revenue estimates increase by 92%, EPS downgraded

Now 23% undervalued after recent price drop

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

High number of new directors

Lyra Therapeutics Inc. Advances Phase 2 Beacon Clinical Trial of Lyr-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study

Lyra Therapeutics, Inc. Announces New LYR-210 data analyses from the Phase 2 LANTERN study

Lyra Therapeutics Announces First Patient Enrolled in Pivotal Enlighten II Clinical Trial of Lyr-210 in Chronic Rhinosinusitis Patients

Consensus revenue estimates fall by 21%

Consensus revenue estimates increase by 17%

Lyra Therapeutics Announces Appointment of Richard Nieman, Md, as Chief Medical Officer, Effective July 11, 2022

Lyra Therapeutics appoints Nieman as Chief Medical Officer

Lyra Therapeutics, Inc.(NasdaqGM:LYRA) dropped from Russell Microcap Value Index

Price target decreased to US$20.67

Lyra Therapeutics: Progress In The Clinic

Consensus forecasts updated

Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis at COSM 2022

High number of new directors

Lyra Therapeutics, Inc. Announces First Patient Treated in Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

A First Look At Lyra Therapeutics

Lyra Therapeutics, Inc. announced that it has received $100.494971 million in funding from a group of investors

Lyra Therapeutics, Inc. announced that it expects to receive $100.494971 million in funding

High number of new directors

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Consensus forecasts updated

Lyra Therapeutics, Inc. Appoints Jim Tobin to Board of Directors

High number of new directors

Lyra Therapeutics, Inc. Announces Enrollment of First Patient in Phase 3 ENLIGHTEN I Clinical Trial of LYR-210 in Adult Patients with Chronic Rhinosinusitis

Lyra Therapeutics Appoints Harlan W. Waksal as Executive Chairman

Lyra Therapeutics, Inc. Announces Initiation of LYR-210 Pivotal Phase 3 Enlighten Program in Surgically Naïve Chronic Rhinosinusitis Patients

Price target decreased to US$24.00

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?

Lyra Therapeutics, Inc. Announces Publication of Positive Lantern Results in the International Forum of Allergy & Rhinology

Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo Technology Platform in the American Journal of Rhinology & Allergy

We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth

Lyra Therapeutics Announces Positive Topline Results of Pharmacokinetic Study of LYR-210 in Patients with Chronic Rhinosinusitis

Lyra Therapeutics, Inc.(NasdaqGM:LYRA) dropped from Russell 3000E Value Index

Lyra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for LYR-210 for the Treatment of Chronic Rhinosinusitis

Price target decreased to US$26.75

We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate

Lyra Therapeutics, Inc., Annual General Meeting, May 26, 2021

How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?

Lyra Therapeutics, Inc. to Report Q4, 2020 Results on Mar 09, 2021

Lyra Therapeutics Announces Appointment of Robert Kern as Chief Medical Officer

New 90-day high: US$14.77

Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth

Lyra Therapeutics, Inc. Appoints Nancy Snyderman, to the Compensation Committee of the Board

Lyra Therapeutics down 19% underwhelming data from lead program

New 90-day high: US$13.88

Lyra Therapeutics: An Intriguing Risk/Reward Proposition Tackling Chronic Rhinosinusitis